Thursday, October 28, 2010

Study Suggests that Gene Mutations May Limit the Effectiveness of Plavix

A box of PlavixImage via WikipediaPeople with certain gene variants who take the blood-thinning drug Plavix (clopidogrel) may be at increased risk for serious complications after coronary stent placement, a new study finds.

Having the gene variants seems to reduce the effectiveness of Plavix and put patients at higher risk of developing blood clots in the stent, suffering a heart attack or stroke, or even dying, according to the research.
"Clopidogrel is one of the most commonly prescribed medications worldwide," said lead researcher Dr. Jessica L. Mega, an instructor in medicine at Brigham and Women's Hospital and Harvard Medical School in Boston.

Enhanced by Zemanta